Bleeding and Cardiogenic Shock: An “Unholy Alliance”?

Courtesy of Dr. Carlos Fava.

Mortality in acute myocardial infarction (MI) with cardiogenic shock (CS) has been reduced over the past two decades. This has been possible thanks to early angioplasty, greater operator (and overall medical team) experience, new antiplatelet therapies, and ventricular assist devices, which have also been somewhat relevant in this setting.

Sangrado y shock cardiogénico ¿Es una asociación “ilícita”?

However, in MI without CS, bleeding is a well-known significant mortality factor. In CS, its mortality risk is 20% or more, and the use of ventricular assist devices increase it between 40% and 70%.

Its real incidence, the factors that cause it, and the severity of its prognosis have not been entirely studied yet.

A subanalysis of the CULPRIT-SHOCK trial included 684 patients. Among them, 147 had bleeding events (21.5%).

There were no differences among groups: the mean age was 70 years old, there was a higher proportion of men, most patients had an ST-segment elevation MI, and over half of them received CPR.


Read also: ESC 2018 | CULPRIT-SHOCK: 1-Year Results Continue to Support Treatment of the Culprit Artery Only.


A high percentage of bleeding events occurred within the first two weeks (57%); a third of them were classified as BARC 3, and 5.4% were fatal.

Patients with bleeding events received mechanical ventilation and treatment with vasoactive substances over a longer period of time. There was a significant association with sepsis, peripheral ischemic complications, new atrial fibrillation, and ventricular fibrillation.

At 30 days, the presence of bleeding events was associated with higher mortality (hazard ratio [HR]: 2.11; 95% confidence interval [CI]: 1.63 to 2.75; p < 0.0001), especially in cases of bleeding higher than 3b.


Read also: The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines.


Extracorporeal membrane oxygenation (ECMO) and Impella were the main risk factors for bleeding.

Conclusion

Risk of bleeding in acute MI with cardiogenic shock is associated with increased mortality.

Courtesy of Dr. Carlos Fava.

Original Title: Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock.

Reference: Anne Freund, et al. J Am Coll Cardiol Intv 2020;13:1182–93.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...